Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model [Pharmacology]

We evaluated the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) against cefepime-resistant Acinetobacter baumannii (N=13) in the neutropenic murine lung infection model. Twelve isolates were meropenem-resistant. In control animals and those that received cefepime or zidebactam alone, mean bacterial growth at 24-h was >2 log₁₀ CFU/lung compared with 0-h controls (6.32±0.33 log₁₀ CFU/lung). WCK 5222 produced a decline in bacterial burden for all isolates (mean reduction, -3.34±0.85 log₁₀ CFU/lung) and demonstrated remarkable potency.

https://ift.tt/2wLkyU5